A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

NCT02091752 ↗

Phase 2 Terminated 3 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.

Timeline

Start: 2014-09
Primary completion: 2015-02
Completion: 2015-02

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated due to low enrollment.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	15 mg	Oral
Subject	Ruxolitinib	Small molecule	20 mg	Oral

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Summary

Timeline

Outcome

Drugs

Indications